Down-regulation of CD45 in T-ALL cell lines harboring JAK1 mutation caused increased proliferation and sensitized cells to the JAK inhibitor ruxolitinib (16, 17). The gene discussed is PTPRC; the disease is acute lymphoblastic leukemia.